Loading...
The Shingrix Vaccine: Information for Patients About Current Recommendations & the National Shortage
Shah, Purvi
Shah, Purvi
Citations
Altmetric:
License
DOI
Abstract
In the US, herpes zoster and related complications have been estimated to result in 1.3 billion dollars of medical costs alone annually. In order to combat this significant public health burden, efforts have been made to vaccinate susceptible populations for herpes zoster. In 2017, the FDA approved Shingrix, a recombinant zoster vaccine that is more effective than its predecessor, Zostavax. Now, patients are being vaccinated for shingles at a higher rate than previous years. As a result, the demand for Shingrix has exceeded supply, leading to an inconsistency in supply. This, in combination with changing recommendations for vaccination has generated confusion and frustration among patients at South Burlington Family Medicine. A patient-centered brochure was created that addresses these concerns and may serve to alleviate some of these sources of stress.
Description
Date
2018-01-01
Journal Title
Journal ISSN
Volume Title
Publisher
Collections
Files
Purvi_Shah_Family_Med_Project_Final.pdf
Adobe PDF, 602.31 KB
- Available to administrators